arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Arbutus Biopharma Corp

ABUS
$4.86 ▼ -0.03 (-0.61%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
57 Visible periods
31 Metrics
Peer-ranked Benchmarks
Price Chart
39
Health
Weak
Bearish
auto_awesome

Analytical Summary

Arbutus Biopharma Corp faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $959.7M
Dividend Yield —
Revenue Growth -90.6% ↘
Op. Margin None
ROIC -1.8% ↘
FCF / Share $-0.03 ↗
Trailing P/E —
Price / Book 3.7x
FCF Yield —
Debt / Equity 0.00
info Valuation on last close. End-of-day price, Sep 24, 2026.

57-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$1.01M
↓ -90.6% —
Net Income Profit after all expenses
$169.69M
— 0.0% —
Operating Margin Operating profit as % of sales
94.3%
↑ +580.5% 0th
FCF / Share Free cash flow per share
$-0.03
↑ +27.2% —
Long-Term Debt Long-term obligations
$0.00
— —
trending_up

Bullish Indicators

  • Debt to EquityDebt to Equity is in the top quartile (lower is better)
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability ↓
1
Returns →
18
Financial Health
97
Cash Quality ↑
72

bar_chart Data from SEC EDGAR XBRL filings

Synced 2 days ago 16 years · 57 quarters